Why the study?
Does long-acting propranolol reduce assaultive behavior in patients with organic brain disease refractory to conventional medications?
Does long-acting propranolol reduce assaultive behavior in patients with organic brain disease refractory to conventional medications?
Long-acting propranolol may be effective in reducing assaultive behavior in patients with organic brain disease who are refractory to conventional medications.
Supports propranolol for refractory assaultive behavior; extends RCT evidence for non-sedating beta-blockade in organic brain disease.
A double-blind, placebo-controlled crossover study was conducted to examine the effects of long-acting propranolol in the treatment of violent behavior associated with organic brain disease in 10 patients whose symptoms had proved refractory to various conventional medications. Long-acting propranolol treatment was associated with reductions of assaultive behavior without apparent sedative effects. Cautions are noted regarding potential undesirable side effects which may necessitate careful patient monitoring during treatment.
No takes yet. Share an insight, caveat, or question.
Greendyke et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: